Intellia Therapeutics (NASDAQ:NTLA) Cut to Hold at Zacks Investment Research
According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. “
NTLA has been the topic of several other research reports. Roth Capital began coverage on Crispr Therapeutics in a research report on Monday, June 10th. They issued a buy rating and a $50.00 price objective on the stock. Robert W. Baird began coverage on Intellia Therapeutics in a research report on Monday. They issued an outperform rating and a $23.00 price objective on the stock. Wedbush reaffirmed an outperform rating on shares of Idera Pharmaceuticals in a research report on Friday, May 3rd. BidaskClub raised Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, June 20th. Finally, Chardan Capital reaffirmed a buy rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $25.31.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.04. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $9.43 million. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. Intellia Therapeutics’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.51) EPS. Analysts expect that Intellia Therapeutics will post -2.43 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers increased its position in shares of Intellia Therapeutics by 60.0% during the fourth quarter. Rhumbline Advisers now owns 48,131 shares of the company’s stock worth $657,000 after acquiring an additional 18,050 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in Intellia Therapeutics in the fourth quarter valued at $136,000. BlackRock Inc. grew its position in Intellia Therapeutics by 4.5% in the fourth quarter. BlackRock Inc. now owns 2,868,738 shares of the company’s stock valued at $39,158,000 after purchasing an additional 124,341 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Intellia Therapeutics by 502.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 260,259 shares of the company’s stock valued at $3,552,000 after purchasing an additional 217,071 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Intellia Therapeutics by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 359,479 shares of the company’s stock valued at $4,906,000 after purchasing an additional 17,771 shares in the last quarter. 74.34% of the stock is currently owned by institutional investors and hedge funds.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Recommended Story: CD Ladder
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.